DDInter1667 DDInter899
Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate. Silodosin was first approved by the FDA in October 2008 and it is also approved in Europe and Canada. Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have a negative impact on the quality of life of patients
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Silodosin {u} (Compound) resembles {v} (Compound) Tamsulosin
Silodosin {u} (Compound) binds {v} (Gene) CYP3A4
Silodosin {u} (Compound) causes {v} (Side Effect) Dizziness
Silodosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Silodosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Silodosin {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Silodosin {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Silodosin (Compound) resembles Tamsulosin (Compound)
Silodosin (Compound) binds CYP3A4 (Gene)
Silodosin (Compound) causes Dizziness (Side Effect)
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Silodosin may lead to a major life threatening interaction when taken with Cobicistat
Silodosin may lead to a major life threatening interaction when taken with Clarithromycin